Vivos Therapeutics Fireside Chat Summary Company Overview - **Company**: Vivos Therapeutics (NasdaqCM: VVOS) - **Industry**: Obstructive Sleep Apnea (OSA) Treatment Key Points and Arguments Strategic Shift and Acquisition - 2025 marked a pivotal year for Vivos, highlighted by the acquisition of the Sleep Center of Nevada (SCN) in June, which represents a transformative shift in the company's business model [2][4] - The motivation behind this pivot is the recognition of the significant health crisis posed by obstructive sleep apnea, which is linked to various comorbidities such as hypertension and cardiovascular diseases [2][3] Technology and Market Opportunity - Vivos possesses a unique technology that can correct obstructive sleep apnea within a year, contrasting with the traditional CPAP machines that patients often reject [3][4] - The company aims to educate the medical community about its FDA-cleared oral appliance devices, which are the only ones approved for moderate to severe OSA, unlike over 200 other devices that are only cleared for mild to moderate cases [26][27] Financial Performance - In Q3, Vivos reported a 76% year-on-year revenue increase, approaching $7 million, largely driven by the integration of SCN [12][21] - SCN generated $2.2 million in diagnostic service revenue, while Vivos contributed $1.3 million in treatment revenue, showcasing a synergistic approach [10][11] Operational Challenges and Demand - The company experienced overwhelming demand post-acquisition, leading to a doubling of facility size and rapid hiring of doctors and staff to meet patient needs [8][9] - Currently, patients are booking appointments into March, indicating a backlog due to high demand [9][20] Cost Dynamics and Profitability - Operating expenses increased by 77% year-over-year, attributed to the SCN acquisition and the need to scale operations [31][33] - Despite high initial costs, the treatment side of the business has much higher margins (60%-70%) compared to the diagnostic side, which is expected to drive profitability as operations stabilize [33][34] Future Growth and Partnerships - Vivos is expanding its sleep center ecosystem through partnerships, such as the recent affiliation in Detroit, which allows for capital-efficient growth without large upfront costs [6][40] - The company is prioritizing growth in the Intermountain West region and is in discussions with potential partners across the U.S. [42] Debt Management and Financial Strategy - Vivos has taken on significant debt to finance the SCN acquisition but believes that the profitability of its new model will allow it to service and eventually retire this debt [48][50] - The company is optimistic about cash flow generation from new revenue streams that require minimal capital outlay, which will help in managing debt [50][52] Market Position and Competitive Landscape - Vivos positions itself as a consolidator in the sleep center treatment business, leveraging its unique technology and growing demand for alternative OSA treatments [46][47] - The company is actively engaging with the medical community to promote its solutions and address the limitations of traditional CPAP treatments [24][28] Additional Important Insights - The demographic of new patients includes a significant number of younger individuals (ages 21-35), indicating a broader market for Vivos' solutions [44] - The company is focusing on educating both patients and healthcare providers about the benefits of its technology, aiming to increase adoption rates [25][26] This summary encapsulates the key discussions and insights from the Vivos Therapeutics fireside chat, highlighting the company's strategic direction, financial performance, and market opportunities in the obstructive sleep apnea treatment space.

Core Insights - Vivos Therapeutics, Inc. is expanding its operations with the grand opening of a new sleep testing and treatment center in Auburn Hills, Michigan, as part of its national expansion strategy to address obstructive sleep apnea (OSA) [1][3] - The new center operates under a capital-efficient affiliation model, allowing Vivos to partner with existing sleep clinics rather than solely relying on acquisitions, which enhances scalability and reduces capital intensity [2][4] - Vivos aims to provide innovative diagnostic and therapeutic solutions for OSA patients, leveraging its proprietary FDA-cleared products to improve patient outcomes and generate higher revenue for affiliated practices [3][4] Company Overview - Vivos Therapeutics focuses on developing and commercializing diagnostic and treatment methods for sleep-related breathing disorders, particularly OSA, with FDA-cleared devices for both adults and children [6][8] - The company emphasizes a non-invasive and non-pharmaceutical approach to treating OSA, known as The Vivos Method, which aims to address the root causes of the disorder rather than relying on traditional treatments like CPAP [9][7] Market Context - OSA affects over 1 billion people globally, with a significant portion undiagnosed, highlighting a substantial market opportunity for Vivos to provide effective treatments [7] - The sleep testing industry has faced pricing pressures, leading to closures and consolidations, which Vivos aims to counteract by offering differentiated treatment options through strategic affiliations [4][5]

Core Insights - Vivos Therapeutics, Inc. is a medical device and healthcare services company focused on diagnosing and treating sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [1][3] - The company will participate in a fireside chat to discuss its strategic business model pivot, operational execution, market opportunities, competitive environment, and growth strategies [2] Company Overview - Vivos Therapeutics, founded in 2016 and based in Littleton, Colorado, specializes in innovative diagnostic and treatment methods for breathing and sleep issues related to dentofacial abnormalities [3][5] - The company's devices are FDA-cleared for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [3] - Vivos' Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for severe OSA treatment in adults and the first for moderate to severe OSA in children [3] Market Context - OSA affects over 1 billion people globally, with 90% undiagnosed, linking it to serious chronic health conditions [4] - Traditional OSA treatments, such as CPAP, often fail to address the root causes of the disorder, indicating a significant market opportunity for innovative solutions [4] Treatment Approach - Vivos employs a proprietary treatment method known as The Vivos Method, which is nonsurgical, noninvasive, and nonpharmaceutical, aiming to provide effective solutions for OSA patients [6]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [8] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9] - Gross profit for Q3 2025 increased to approximately $3.9 million, with a gross margin of 58%, slightly down from 60% in Q3 2024 [11] - Net loss increased to $5.4 million in Q3 2025 and $14.3 million for the first three quarters of 2025 [12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada (SCN) and $1.3 million from new treatment centers [8] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new model [9] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at SCN, indicating substantial growth potential [23] - Over 210,000 OSA patients have been tested by SCN providers since 2019, with many potential patients dissatisfied with CPAP units [23] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [18] - The establishment of Sleep and Airway Medicine Centers (SAMC) in Nevada is part of the strategy to provide comprehensive treatment options for OSA patients [20] - Future initiatives include expanding diagnostic and treatment services, establishing a pediatric OSA program, and collaborating with specialty medical groups [29] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating the company's ability to monetize its technology for treating sleep-related disorders [15] - The company expects revenue growth to continue as new dental providers and nurse practitioners are onboarded, which will optimize revenue generation [39] - Management anticipates that the SAMC operations will achieve contribution margins of 50%-60% at steady-state [43] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - The acquisition of SCN has allowed the company to recognize new revenue streams from OSA diagnostic and treatment services [57] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new providers are deployed, with a ramp-up period of three to six months for optimal revenue levels [39][40] Question: What are the reasonable operating expenses for the next quarters? - SAMC operations are expected to achieve contribution margins of 50%-60% at steady-state, with current expenses being higher due to upfront investments [43] Question: Update on cash flow break-even goals? - The goal is to achieve cash flow break-even, with expectations that profits from SAMC operations will contribute to this goal in the near future [46] Question: How should investors view the company now and in six months? - Management believes the current model is replicable and scalable, with significant growth potential ahead, making it an exciting time for investors [52][56] Question: How does revenue recognition differ between models? - Revenue recognition varies based on the model, with acquisitions allowing for immediate recognition upon product shipment, while contractual alliances may involve profit-sharing arrangements [57]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [8] - For the nine months ended September 30, 2025, revenue increased approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9] - Gross profit for Q3 2025 increased approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11] - Net loss increased to $5.4 million in Q3 2025 and $14.3 million for the first nine months of 2025 [12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada and $1.3 million from new treatment centers [8] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at Sleep Center of Nevada, indicating substantial growth potential [26] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [26] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and testing centers aims to increase patient access to Vivos technology and improve financial returns [20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is central to the new model, focusing on educating and evaluating patients for treatment [24] - Future initiatives include expanding diagnostic and treatment services, establishing a pediatric OSA program, and collaborating with specialty medical groups [32] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating the company's ability to monetize its technology for treating sleep-related disorders [17] - The company expects revenue growth to continue as new dental providers and nurse practitioners are onboarded, with a projected ramp-up period of three to six months for optimal revenue levels [42][44] - Management believes the new model is replicable and scalable across multiple markets, with a focus on achieving cash flow break-even in the near future [50][56] Other Important Information - The company has secured $14.2 million in net cash from financing activities, with total liabilities of $23.1 million and cash and cash equivalents of $3.1 million as of September 30, 2025 [13] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new providers are deployed, with a ramp-up period of three to six months for optimal revenue levels [41][44] Question: What are the reasonable operating expenses for the next quarter? - SAMHSA operations are expected to achieve contribution margins of 50%-60% at steady-state, with current expenses being higher due to upfront investments in personnel [46][47] Question: Update on cash flow break-even goals? - The goal is to achieve cash flow break-even, with expectations that profits from SAMHSA center operations will contribute to this goal in the near future [49][50] Question: How should investors view the company now and in six months? - Management believes the company has finally settled on a monetization model that leverages its technological advantages, with significant growth potential ahead [55][56]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [7][9] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9][12] - Gross profit for Q3 2025 increased by approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11][12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada, and $1.3 million from new treatment centers [8][9] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9][10] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at the Sleep Center of Nevada, indicating substantial growth potential [24] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [24] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [19][20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is part of the strategy to educate and evaluate patients for treatment options [22][30] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating a significant inflection point in the company's ability to monetize its technology for treating sleep-related disorders [16][19] - The company expects revenue growth to outpace expenses as new teams are deployed and operational efficiencies are realized [23][33] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - General and administrative expenses increased by approximately $5.7 million, primarily due to costs associated with the Sleep Center of Nevada operations [12] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new dental providers and nurse practitioners are added to the teams [35] Question: What is the expected ramp-up time for revenue generation? - A ramp-up period of approximately three to six months is anticipated to reach optimized revenue levels [36] Question: What are the expected contribution margins for SAMHSA operations? - Steady-state operations are expected to yield contribution margins of 50%-60% [38] Question: What is the goal for cash flow break-even? - The goal is to achieve cash flow break-even, with ongoing efforts to manage growth and operational expenses [39] Question: How should investors view the company now and in six months? - Management believes the company has finally found a monetization model that aligns with its technological advantages, indicating strong future growth potential [41][42]

Revenue Performance - Revenue for Q3 2025 was $6.8 million, a 78% increase sequentially and a 76% increase year-over-year compared to Q3 2024's $3.9 million[5] - Total revenue for the three months ended September 30, 2025, was $6,783 million, a significant increase from $3,860 million in the same period of 2024, representing a growth of 76.5%[21] - Product revenue reached $2,195 million for the three months ended September 30, 2025, compared to $1,958 million in 2024, marking an increase of 12.1%[21] - Service revenue surged to $4,588 million for the three months ended September 30, 2025, up from $1,902 million in 2024, reflecting a growth of 141.5%[21] Profitability and Loss - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, while gross margin declined to 58% from 60% year-over-year[5] - Gross profit for the three months ended September 30, 2025, was $3,937 million, compared to $2,334 million in 2024, indicating an increase of 68.8%[21] - The operating loss for Q3 2025 increased to $4.7 million from $2.6 million in Q3 2024[5] - Operating loss for the three months ended September 30, 2025, was $(4,734) million, widening from $(2,645) million in the same period of 2024[21] - Net loss for the three months ended September 30, 2025, was $(5,400) million, compared to $(2,616) million in 2024, representing an increase in loss of 106.8%[21] - Net loss per share (basic and diluted) for the three months ended September 30, 2025, was $(0.49), compared to $(0.40) in 2024[21] Expenses and Financial Position - Operating expenses for Q3 2025 were $8.7 million, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and depreciation expenses related to the SCN acquisition[5] - Total operating expenses for the three months ended September 30, 2025, were $8,671 million, up from $4,979 million in 2024, reflecting a rise of 74.5%[21] - Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, down from $6.3 million at the end of 2024[5] - Stockholders' equity was $2.5 million as of September 30, 2025, compared to $8.0 million at the end of 2024[5] Strategic Initiatives - The acquisition of The Sleep Center of Nevada contributed $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025[5] - Vivos plans to expand its model into additional major markets beyond Las Vegas through acquisitions or contractual alliances with sleep medical practices[3] - The company is actively working to add new sleep optimization teams in 2026 to reduce cash burn and create potential for profitable operations[4] - Vivos has entered into a management agreement with MISleep Solutions LLC to provide its treatments and services in Auburn Hills, Michigan, with patient services expected to begin in early December 2025[7] Shareholder Information - The weighted average number of shares outstanding (basic and diluted) increased to 10,963,590 for the three months ended September 30, 2025, from 6,615,320 in 2024[21] - Non-operating income (expense) included other expense of $(679) million for the three months ended September 30, 2025, compared to $(18) million in 2024[21]

Core Insights - Vivos Therapeutics reported a 78% sequential revenue growth in Q3 2025, driven by the first full quarter of operations from the Sleep Center of Nevada acquisition, with a year-over-year revenue increase of 76% [2][4] - The strategic pivot from a dental distribution model to direct affiliations and acquisitions of medical sleep practices is yielding positive results, as evidenced by the revenue contributions from the Sleep Center of Nevada [2][4] - The company is optimistic about growth potential in the Las Vegas area and plans to expand its model into other major markets [2][6] Financial Performance - Q3 2025 revenue reached $6.8 million, up from $3.9 million in Q3 2024, while revenue for the nine months ended September 30, 2025, was $13.6 million compared to $11.3 million in the same period of 2024 [4][23] - Gross profit for Q3 2025 was $3.9 million, reflecting an increase from $2.3 million in Q3 2024, with gross margins at 58% compared to 60% in the previous year [4][11] - Operating expenses rose to $8.7 million in Q3 2025, a 74% increase from $5.0 million in Q3 2024, primarily due to increased headcount and expenses related to the SCN acquisition [11][23] Strategic Initiatives - The acquisition of the Sleep Center of Nevada has introduced new revenue streams, contributing $2.2 million in diagnostic sleep testing revenue and $1.3 million in treatment center revenue during Q3 2025 [4][23] - Vivos is implementing an updated sleep practice affiliation model to collaborate with sleep centers that prefer not to be acquired, allowing them to offer Vivos' diagnostic and treatment options [5][6] - The company is actively seeking similar management agreements in other major markets to expand its reach and service offerings [6] Market Outlook - Vivos anticipates significant local market growth potential in Las Vegas, with patient bookings extending into February 2026 as they work to enhance operations and capacity [2][4] - The company plans to continue adding new sleep optimization teams in 2026, which is expected to reduce cash burn and pave the way for profitable operations [3][11]

Revenue Performance - Total revenue for Q3 2025 was $6,783,000, a 76% increase from $3,860,000 in Q3 2024[18] - Product revenue increased to $2,195,000 in Q3 2025, up 12% from $1,958,000 in Q3 2024[18] - Service revenue surged to $4,588,000 in Q3 2025, compared to $1,902,000 in Q3 2024, representing a 142% increase[18] - For the three months ended September 30, 2025, the company incurred a net loss of $5.4 million, compared to a net loss of $2.6 million for the same period in 2024[149] - Pro forma net revenue for the three months ended September 30, 2025, was $6.8 million, compared to $5.8 million for the same period in 2024[88] Financial Losses - Operating loss for Q3 2025 was $(4,734,000), compared to $(2,645,000) in Q3 2024, indicating a worsening of 79%[18] - Net loss for Q3 2025 was $(5,400,000), compared to $(2,616,000) in Q3 2024, representing a 106% increase in losses[18] - For the nine months ended September 30, 2025, the net loss was $14.276 million, compared to a net loss of $8.309 million for the same period in 2024, representing a 72% increase in losses[24] Assets and Liabilities - Total assets as of September 30, 2025, were $25,644,000, significantly up from $15,284,000 as of December 31, 2024[15] - Total liabilities increased to $23,112,000 as of September 30, 2025, compared to $7,330,000 at the end of 2024[15] - Stockholders' equity decreased to $2,532,000 as of September 30, 2025, down from $7,954,000 as of December 31, 2024[15] Cash Flow and Financing - Net cash used in operating activities was $11.451 million for the nine months ended September 30, 2025, compared to $9.751 million for the same period in 2024, indicating a 17% increase in cash outflow[24] - The company reported net cash provided by financing activities of $14.223 million for the nine months ended September 30, 2025, compared to $14.822 million for the same period in 2024, showing a slight decrease of 4%[24] - Cash and cash equivalents at the end of the year were $3.087 million, down from $6.311 million at the end of the previous year, reflecting a decrease of 51%[24] Strategic Acquisitions and Business Model - The company acquired all operating assets of The Sleep Center of Nevada for a total consideration of $6.0 million in cash and $1.5 million in common stock, marking a strategic expansion into sleep disorder treatment[29] - The company is exploring additional acquisitions and collaborations with medical sleep practices to expand its business model and revenue streams[37] - The company has shifted its focus to direct patient services, including home sleep screenings and telemedicine, under its new business strategy[32] Revenue Recognition and Customer Contracts - Revenue recognition follows ASC Topic 606, with legacy VIP enrollment revenue expected to continue through 2026[44] - Estimated customer life for VIP contracts ranges from 14 to 27 months, impacting revenue recognition timing[48] - Revenue from appliance sales is recognized upon transfer of control to the VIP, with the company acting as the principal in the transaction[59] Market and Operational Challenges - The Federal Reserve's elevated interest rates pose a risk to the company's revenue, earnings, and access to capital[207] - Changes in U.S. trade policy and tariffs may materially impact the company's sourcing strategy and competitiveness of contract manufacturers[205] - Ongoing geopolitical tensions, including the war in Ukraine and Middle East hostilities, could adversely affect demand for the company's products and capital market stability[209] Compliance and Regulatory Matters - The company received a notice from Nasdaq regarding non-compliance with the $2,500,000 minimum stockholders' equity requirement as of March 31, 2024[211] - Following a $7.5 million equity private placement, the company reported compliance with the equity requirement and received continued listing approval from Nasdaq[211] - The company is exploring additional equity capital financings to maintain compliance with Nasdaq's equity requirement[212]